PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Procept Biorobotics Corp'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Procept Biorobotics Corp'in toplam varlıkları $0 olup, net 損失 $0'dir.
PRCT'ün temel finansal oranları nelerdir?
Procept Biorobotics Corp'in cari oranı 0, net kâr marjı 0, hisse başına satış $0'dir.
Procept Biorobotics Corp'in geliri segment veya coğrafya bazında nasıl dağılıyor?
Procept Biorobotics Corp 最大收入來源為 Hand Pieces and Other Consumables,在最近的收益報告中收入為 121,456,000。就地區而言,United States 是 Procept Biorobotics Corp 的主要市場,收入為 200,472,000。
Procept Biorobotics Corp kârlı mı?
無, son mali tablolara göre Procept Biorobotics Corp'in net 損失 $0'dir.
Procept Biorobotics Corp'in herhangi bir yükümlülüğü var mı?
無, Procept Biorobotics Corp'in yükümlülüğü 0'dir.
Procept Biorobotics Corp'in tedavüldeki hisse sayısı kaçtır?
Procept Biorobotics Corp'in toplam tedavüldeki hisse sayısı 0'dir.